On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of the Phase 1/2 clinical trial of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, using Dynavax’s CpG 1018ﾙ adjuvant in 153 healthy adults aged 18 to 55 years. Based on these results, Valneva planned to commence a pivotal Phase 3 clinical trial by the end of Apr. 2021, subject to regulatory approval.